Researchers analyzed seven previous studies involving over 107,000 adults who have both type 2 diabetes and peripheral artery disease (PAD). PAD narrows the arteries in the legs, which can cause pain while walking and increase the risk of serious limb problems. They wanted to see if a class of diabetes medications called GLP-1 receptor agonists (like liraglutide and semaglutide) could help with walking ability or reduce limb complications.
The analysis found that in randomized controlled trials (the strongest type of study), these medications were linked to a significant improvement in how far people could walk. In separate observational studies, the drugs were associated with a lower risk of lower extremity amputation. However, the studies on amputation risk were not randomized trials and showed a lot of variation in their results.
It's important to be cautious about the amputation finding. The researchers rated this evidence as 'very low certainty' due to the study designs and high inconsistency between studies. The randomized trials did not show a clear effect on major adverse limb events. This means that while the walking distance improvement is more solid, the potential link to reduced amputations needs much more research to confirm. Readers should understand this as an early signal for researchers to investigate further, not as proof that these drugs prevent amputations.